Yang Sen is burning $1 billion for this product. Why?

On May 26, YANGSEN company and protago NIST therapeutics company reached a global exclusive license and cooperation agreement on the development, production and commercialization of ptg-200, the first new drug of interleukin-23 receptor (IL-23R) antagonist The indications of the drug are Crohn's disease (CD) and ulcerative colitis (UC) Yang Senhao's $1 billion gamble is undoubtedly to enhance the company's competitiveness in new products in the field of autoimmune diseases, and to challenge new drugs in the field of Crohn's disease and ulcerative enteritis   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif; font-size: 16px; line-height: 25.6px; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); Box-sizing: border-box! Im portant; word-wrap: break-word! Im portant; > inflammatory bowel disease should not be underestimated The incidence rate of inflammatory bowel disease (IBD) from large molecule drugs to the front stage is 149/10 million, and IBD is characterized by complexity, long duration and fickle characteristics It is a very difficult disease in the field of global treatment Ulcerative colitis and Crohn's disease are inflammatory bowel diseases with similar but different characteristics In the past 20 years, under the influence of Western fast food diet, smoking, work and life pressure and living environment, the total number of IBD cases in China is about 400000 In the last 10 years, ulcerative colitis increased more than 2.3 times, Crohn's disease even increased more than 15 times There is no definite conclusion about the cause of ulcerative colitis It is believed that the disease is related to genetic factors, with autoimmune mechanism as the root and infection and nerve factors as the inducement The lesions are mainly in rectum and sigmoid colon The study shows that ulcerative colitis incidence rate is high in the middle and old age population, 28.45% in age group 30-39, 21.98% in 50-59 years old age group, and city population is obviously higher than rural population Among them, total colitis was 40.8%, rectosigmoid colitis 27.2%, left hemicolitis 18.6%, rectitis 13.4% Chronic ulcerative colitis increases the possibility of canceration, but the possibility of canceration is only 3% - 5% The canceration rate of more than 10 years is 5% - 10% After 30 years, the canceration rate is 15% - 40% The maintenance treatment after the acute attack of ulcerative colitis is an important measure to prevent the recurrence and pathological changes of ulcerative colitis At present, there are two main kinds of drugs for ulcerative colitis at home and abroad, one is glucocorticoid, the other is mesalazine Aminosalicylic acid preparation has been developed from sulfasalazine to four varieties of balsalazine, Osalazine and 5-aminosalicylic acid In clinic, the maintenance therapy of salicylic acid is often used, which can reduce the recurrence rate of disease and improve the quality of life of patients Antibody drugs are in the initial stage In 2015, the National Institutes of health and clinical optimization (NICE) released the guideline of biological drug treatment for adult moderate and severe active ulcerative colitis It is recommended that REMICADE, simponi and Humira be used in adult patients with moderate to severe active ulcerative colitis, so as to make the macromolecular drugs move from behind the scenes to the front of the stage The main clinical drugs for inflammatory bowel diseases are aminosalicylic acid, glucocorticoid, immunomodulator and monoclonal antibody The monoclonal antibodies approved by FDA for the treatment of UC and CD are mainly adalimumab, infliximab, utizumab, golimumab, cetuzumab and vidozumab The chemicals used to treat UC and CD are methadone, which accounts for a quarter of the total market According to relevant data, the market size of prescription drugs for inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) in the United States was US $4.26 billion in 2011, US $8 billion in 2017, US $100 in 2020, and antibody drugs will play an important role   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif; font-size: 16px; line-height: 25.6px; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> in the domestic market, two typical varieties enter the medical insurance According to the data of 2017 national medical insurance drug catalog, the collected antidiarrheal, enteric anti-inflammatory and enteric anti infective drugs are divided into 8 categories and 14 drugs, including enteric anti infective, intestinal adsorbent, carbohydrate containing electrolyte, gastrointestinal motility reducing drug, enteric anti-inflammatory drug, antidiarrheal micro organism, digestive enzyme drug and other antidiarrheal drugs The drugs for ulcerative colitis are sulfasalazine and sulfasalazine The basic drugs commonly used in clinic of Crohn's disease and ulcerative colitis in China are adrenocortical hormone, sulfasalazine, mesalazine, balsalazine, and immunosuppressant infliximab, azathioprine and methotrexate According to the data of chemical medicine terminal (HDM) system of China's urban public hospitals on Intranet, the market of Crohn's disease and ulcerative colitis in the public hospitals in key cities in 2016 was 350 million yuan (corticosteroids were not included), an increase of 18.38% over the previous year The top 5 drugs of Crohn's disease and ulcerative colitis market in China are mesalazine, infliximab, sulfasalazine, methotrexate and azathioprine; it is estimated that the sales of inflammatory bowel disease in the six major markets, including the three major terminals of urban public hospitals, county-level public hospitals, urban community centers, township hospitals, physical medicine stores and online stores, will reach 5 billion yuan At the end of the 20th century, mesalazine was introduced into China In 2000, the sustained-release tablets and suppositories of ferring company were imported and registered, which were used in clinical practice in China under the trade name of Pentasa Later, the sustained-release granules of ethepharm pharmaceutical company in France came into the market After that, the enema solution, suppository and enteric coated tablets of Dr Falk Pharma GmbH were registered in China under the trade name of salofalk So far, CFDA has approved the listing of mesalazine preparations of Hengcheng Pharmaceutical Group Huainan company, sunflower Pharmaceutical Group jiamusiluling pharmaceutical, Heilongjiang Tianhong Pharmaceutical Co., Ltd and Shanghai Aidi pharmaceutical According to the data of MI Nei net HDM system, in 2016, the terminal drug use of mesalazine in public hospitals in key cities in China was 178 million yuan, an increase of 15.35% over the previous year The manufacturers and shares of top 5 are salofalk (Germany) Co., Ltd accounting for 39.13%, Shanghai aidifa (Shanghai) Co., Ltd accounting for 32.16%, Huiling (Shanghai) Co., Ltd accounting for 14.11%, sunflower (sunflower) pharmaceutical industry (jiamusiluling) accounting for 7%, Heilongjiang Tianhong (Heilongjiang) accounting for 5.63% Overall analysis shows that imported drugs and domestic drugs are in a balanced situation Mesalazine has a significant inhibitory effect on the inflammation of the intestinal wall, which can inhibit the synthesis of prostaglandins and the formation of inflammatory mediators leukotrienes It has better effect on the connective tissue of intestinal wall with inflammation For ulcerative colitis, ulcerative colitis and Crohn's disease has a better effect The dosage forms of mesalazine were 42.39% in sustained-release tablets and enteric coated tablets, 32.16% in sustained-release granules, 8.66% in enema solution and 16.79% in external suppositories Sulfasalazine is a sulfanilamide oral anti-inflammatory drug It was used in ulcerative colitis by Dana svartz in 1942 It has been used for more than half a century It is a milestone drug in the treatment of ulcerative colitis in the world After oral administration, sulfasalazine was split into 5-aminosalicylic acid and SULFAPYRIDINE by bacteria in colon, which could alleviate inflammatory reaction For the treatment of ulcerative colitis and Crohn's disease The drug has antibacterial, anti-inflammatory and immunosuppressive effects, can inhibit the acute attack of ulcerative colitis, and prolong its remission period According to the data of midnet HDM system, in 2016, sulfasalazine was used in public hospitals in key cities of China, 14.6 million yuan, an increase of 12% over the previous year Sulfasalazine is a domestic drug monopoly, with 60 companies including Shanghai Xinyi balance, Guangdong Qiangji, Shanxi Tongda, Shanghai Fuda, Shanghai Zhongxi Sanwei and Jiangsu Yuanheng occupying 98% of the market     none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif; font-size: 16px; line-height: 25.6px; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> the final force of biological antibody entered the IBD market The National Institute of health and clinical optimization (NICE) published the final guidance recommendations for biological treatment of adult patients with moderate and severe active ulcerative colitis Infliximab, golimumab and adalimumab are recommended for use within the authorization In September 2007, Xi'an Janssen company announced that infliximab, a tumor necrosis factor inhibitor, was officially listed in China, the trade name of Lek Infliximab is a biological agent approved by China CFDA for the treatment of rheumatoid arthritis, ankylosing spondylitis and Crohn's disease Drug over recognize, combine and block TNF - α in patients, reduce the inflammatory response caused by TNF - α, alleviate disease symptoms, and inhibit the erosion of human tissue damage According to the data of Intranet HDM system, in 2016, the amount of infliximab used in public hospitals in key cities in China was 92.58 million yuan, an increase of 14.85% over the previous year With the adjustment of domestic medical insurance policy and the expectation of health, the antibody market will develop rapidly   none="shifuMouseDown('shifu_t_002')" style="margin: 1em auto; padding: 0.5em 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif; font-size: 16px; line-height: 25.6px; border: none; text-align: center; width: 670px; box-sizing: border-box !im portant; Word wrap: break word! Im portant; "> conclusion this cooperation enables protago NIST therapeutics to obtain sufficient funds and promote the development of R & D and clinical pipeline of the company And the drugs under research of protago NIST therapeutics will also improve the product line of Janssen company in IBD treatment, so it seems that this cooperation is a win-win for both parties As for the future results, we look forward to market verification.